Electrophysiology Devices Market Size, Share & Trends Analysis Report By Device Type (Ablation Catheters, Diagnostic Catheters, Laboratory Devices, Access Devices), By Indication, By End Use, By Region, And Segment Forecasts, 2025 - 2030

Electrophysiology Devices Market Trends

The global electrophysiology devices market size was estimated at USD 12.9 billion in 2024 and is projected to grow at a CAGR of 15.1% from 2025 to 2030. Increasing use of electrophysiology (EP) tests in treating and diagnosing heart diseases, such as atrial fibrillation, growing demand for devices for cardiac rhythm management for constant monitoring, and increasing application of these devices in out-of-hospital settings are propelling the industry growth. The prevalence of heart failure, cardiac arrest, and atrial fibrillation among millennials is rising due to sedentary lifestyles, smoking, excessive alcohol consumption, and others. According to the CDC, approximately 12.1 million Americans will be suffering from atrial fibrillation by 2030. 

The growing number of catheter ablation procedures will positively impact the global market. As the number of ablation procedures rises, a direct increase in demand for ancillary products is observed. Furthermore, electrophysiology devices include electrophysiology (EP) devices that enhance maneuverability for navigating complex anatomies, provide greater flexibility for reaching targeted areas, improve compatibility, and enhance visualization capability through integrated imaging capabilities. According to an article published by Elsevier Inc. in March 2023, the annual rate of cardiac electrophysiology (EP) procedures increased from 817.9 in 2013 to 1,089.68 per 100,000 beneficiaries in 2019 within the U.S.

The growing arrhythmia burden is expected to propel opportunities in the global market. According to an article published by Johnson & Johnson Services, Inc. in 2021-22, the prevalence of atrial fibrillation (AFib) was over 7 million in the U.S., 20 million in Asia Pacific, 14 million in Europe, and nearly 2 million in Latin America. In Europe, countries such as France, Germany, Italy, and the UK witness over 1 million AFib cases. Furthermore, the region has an aging population, leading to a projected 70.0% increase in AFib cases within the next few years (by 2030). By 2050, Europe is anticipated to witness the most significant rise in AFib cases globally. Consequently, AFib-related stroke events, hospitalizations, and outpatient visits are expected to surge substantially, creating an increased demand for electrophysiology devices.

Market Characteristics & Concentration

The market is highly consolidated, with leading players introducing novel products. The market growth stage is high, and the pace of market growth is accelerating. For instance, in January 2024, GE HealthCare introduced the Prucka 3 Digital Amplifier as an innovative platform for innovation in EP. This next-generation system offers enhanced capabilities for diagnosing and treating heart rhythm disorders.

The market is witnessing continuous research and development, such as adopting 3D mapping systems, the production of wireless and wearable devices for continuous monitoring, and the integration of artificial intelligence (AI) in electrophysiology procedures. Manufacturers are focusing on introducing novel technologies to produce more accurate, cost-effective, and user-friendly EP devices.

A high level of M&A activities characterizes the market. The main reason for the frequent acquisitions in this market is the technological soundness of small players with their robust product pipelines. It allows the key players to improve their market share, expand their product portfolio, and provide opportunities to be the first entrant into a niche market segment. For instance, in November 2022, the company completed the acquisition of Obsidio, Inc., a medical technology company. This acquisition was expected to boost the company's cardiac devices portfolio.

The stringent regulatory framework for approval and commercialization of electrophysiology devices impedes market growth. Compliance with regulatory standards further often results in product recalls, reducing patient and healthcare participant confidence. For instance, in January 2024, Abbott was issued a Class II device recall notice by the U.S. FDA for its TactiFlex Ablation Sensor Enabled Ablation Catheter.

Key companies in the global market are also focusing on market expansion. For instance, in February 2024, Terumo Corporation, a key med-tech player, announced the opening of its new manufacturing facility in Puerto Rico. The facility is close to 64,000 square feet.

Device Type Insights

Based on device type, the ablation catheters segment led the market with the largest revenue share of 45.53% in 2024. An ablation catheter is used to control irregular heartbeats that cannot be treated with medication. The ablation catheter segment comprises radiofrequency (RF) ablation, cryoablation, and pulse field ablation. Growing heart failure and arrhythmia incidences, awareness regarding the electrophysiology procedures’ reliability, advancement in EP technologies, and increasing minimally invasive procedures are factors responsible for the segment's dominance. For instance, in January 2024, Boston Scientific Corporation received approval for the FARAPULSE Pulsed Field Ablation System. This system offers an innovative approach to performing cardiac ablation.

The diagnostic catheters segment is anticipated to register at a significant CAGR during the forecast period. Diagnostic catheters are used to investigate and evaluate patients with suspected cardiovascular diseases. These comprise EP mapping devices, cardiac output catheters, and angiography catheters. In July 2023, Biosense Webster, Inc. launched a mapping catheter, OPTRELL. OPTRELL is a high-density diagnostic catheter that provides high-definition EP mapping of complex cardiac arrhythmias.

Indication Insights

Based on indication, the atrial fibrillation segment led the market with the largest revenue share of 73.64% in 2024. It is the most common type of arrhythmia associated with a high risk of stroke and blood clotting. According to the British Heart Association, in 2022, approximately 1.5 million of the UK population suffer from atrial fibrillation. In addition, an expected 270,000 individuals aged 65 years and above have undiagnosed atrial fibrillation in the country. The high prevalence of the disease is responsible for the prominent share of the segment.

In recent years, innovative smartphone applications have been introduced for arrhythmic patients that can connect them with healthcare professionals. Moreover, inpatient facilities and clinical settings are taking the initiative to involve arrhythmia care in their treatment routine.

End Use Insights

Based on end use, the inpatient facility segment led the market with the largest revenue share of 83.47% in 2024. The adoption of technologically advanced cardiac rhythm management and EP systems by interventional cardiologists and the rising burden of cardiovascular disease (CVD) is responsible for the dominant share of the segment. The number of arrhythmia procedures in inpatient facilities is estimated to increase over the coming years owing to the availability of a skilled team of cardiologists and a well-equipped facility. Furthermore, a growing number of patients approach hospitals due to proper reimbursement facilities and accessibility to treatment, which drives the segment.

The outpatient facilities segment is projected to grow at the fastest CAGR during the forecast period. A shift towards minimally invasive outpatient procedures and significant cost savings augment the segment's growth. For instance, a study by Health Affairs revealed that ASC procedures are cost and time-effective. It takes around 25% less time than inpatient facilities, with USD 360 to 1,000 savings per patient owing to the lower fixed costs. Furthermore, government initiatives to reduce the cost of treatment and favorable reimbursement policies are propelling segment growth. The Centers for Medicare & Medicaid Services (CMS) extended ambulatory surgical coverage for cardiac interventional procedures, such as pacemaker implants, endovenous ablation, and catheterization procedures.

Regional Insights

North America electrophysiology devices market dominated the largest revenue share of 49.45% in 2024. The rising incidence of cardiovascular disease, advanced healthcare infrastructure, and the presence of key players. In addition, the increasing number of patients undergoing surgeries and the rising awareness about minimally invasive surgeries are expected to propel market growth in North America.

U.S. Electrophysiology Devices Market Trends

The U.S. electrophysiology devices market is accounted for the revenue share of over 85.0% in 2024 and is expected to grow at the fastest CAGR during the forecast period. In the U.S., advanced healthcare infrastructure, the growing patient pool, and the increasing number of new product launches are some of the major factors expected to propel market growth over the forecast period.

Europe Electrophysiology Devices Market Trends

The Europe electrophysiology devices market held the second-largest revenue share in 2024.Europe has a robust healthcare system, witnessing a shift from in-patient to out-patient care due to the growing presence of several medical equipment companies offering catheters in the region.

The Germany electrophysiology devices market accounted for the largest revenue share of 27.8% in 2024. The increasing prevalence of cardiac disorders is expected to improve the demand for catheters in treating narrowing arteries in patients.

The electrophysiology devices market in the UK held the third-largest market share in Europe in 2024. The prevalence of cardiovascular diseases, such as coronary artery disease, ischemic heart disease, and other heart-related disorders in the UK is expected to increase the demand for EP devices.

The France electrophysiology devices market is anticipated to witness at a significant CAGR of 13.9% during the forecast period. Growth in France is likely to be driven by the rising incidence of cardiovascular diseases, a growing number of hospitals & clinics, and lifestyle changes in the population.

Asia Pacific Electrophysiology Devices Market Trends

The electrophysiology (EP) devices market in Asia Pacificis projected to register at the fastest CAGR of 14.8% during the forecast period. The increasing health awareness, a developing private hospital sector, growing government support & spending, the rising prevalence of cardiovascular diseases, and the growing availability of insurance policies will likely contribute to market growth over the coming decade.

The China electrophysiology (EP) devices market held the largest revenue market share at 32.3% in 2024.  The increasing prevalence of cardiovascular disease in China due to high blood pressure, unhealthy lifestyle, aging population, urbanization, and high cholesterol levels are anticipated to boost the market.

The electrophysiology (EP) devices market in Japan held the second largest market share in Asia Pacific in 2024. Japan is considered a major market for electrophysiology devices in the Asia Pacific. Cardiovascular disorders, including heart diseases such as atrial fibrillation and stroke, have a considerable impact on Japan’s life expectancy and medical costs.The growing prevalence of cardiovascular diseases is anticipated to drive market growth in Japan.

The India electrophysiology (EP) devices market is expected to grow at the fastest CAGR of 16.1% during the forecast period. The increasing prevalence of coronary artery disease is expected to boost the need for interventional ablation procedures, which is anticipated to drive the market in India. In addition, an increasing number of private players and hospitals run by government organizations are providing cardiovascular disease treatment procedures, which is anticipated to propel market growth.

Latin America Electrophysiology Devices Market Trends

The electrophysiology (EP) devices market in Latin America is expected to grow at the fastest CAGR during the forecast period. CVD is one of the leading causes of death in Latin American countries.Atrial fibrillation (AFib) is estimated to be amongst the top four cardiovascular diseases in the region.

The Mexico electrophysiology (EP) devices market is expected to grow at a significant CAGR during the forecast period, due to various factors, such as the high incidence of chronic heart diseases, improved medical facilities, and favourable regulatory policies. According to an article published by Johnson and Johnson, Afif affects nearly 417,000 people in the country.

Middle East & Africa Electrophysiology Devices Market Trends

The electrophysiology (EP) devices market in Middle East & Africa is expected to grow at a lucrative CAGR during the forecast period. This region is one of the significant developing markets for medical devices. Increased prevalence of ischemic heart disease, vascular disease, and coronary artery disease, as well as a rise in public awareness about the need for prompt diagnosis & usage of advanced devices, are projected to be the main factors driving market demand over the forecast period.

The South Africa electrophysiology (EP) devices market held the largest revenue share at 22.5% in 2024. Technology is altering the delivery of healthcare in Africa, allowing more people in distant locations and around the world to receive better care. Moreover, South Africa serves as a key geographic location for the rest of African countries to undergo ablation procedure which drives growth. 

Key Electrophysiology Devices Company Insights

Leading companies in the global market are enhancing their offerings and incorporating new technologies to expand their customer reach, secure a greater market share, and diversify their application range. For example, Medtronic announced the expansion of its product application line, Freezor and Freezor Xtra Cardiac Cryoablation Focal Catheters. These products were granted expanded FDA approval to treat atrioventricular nodal re-entrant tachycardia (AVNRT).

Recent Developments

• In August 2023, Biosense Webster received approval for various atrial fibrillation ablation products that can be utilized in a workflow without fluoroscopy during catheter ablation procedures.

• In May 2023, Abbott obtained approval from the U.S. Food and Drug Administration (FDA) for TactiFlex Ablation Catheter, Sensor Enabled, the first ablation catheter with contact force technology and a flexible tip. The TactiFlex catheter can treat atrial fibrillation (AFib) with reduced procedure times and better safety than previous-generation catheters.

• In February 2022, Boston Scientific Corp. acquired Baylis Medical Company Inc., specializing in advanced transseptal solutions for the left side of the heart in catheter-based procedures. 

Electrophysiology Devices Market Report Scope

Global Electrophysiology Devices Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global electrophysiology devices market report based on the device type, indication, end use, and region:

• Device Type Outlook (Revenue, USD Billion, 2018 - 2030)

  • Ablation Catheters

    • Radiofrequency (RF) Ablation

    • Cryoablation

    • Pulse Field Ablation

  • Diagnostic Catheters

  • Laboratory Devices

  • Access Devices

• Indication Outlook (Revenue, USD Billion, 2018 - 2030)

  • Atrial Fibrillation (AF)

  • Non-Atrial Fibrillation

• End Use Outlook (Revenue, USD Billion, 2018 - 2030)

  • Inpatient Facilities

  • Outpatient Facilities

  • Others

• Regional Outlook (Revenue, USD Billion, 2018 - 2030)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East & Africa (MEA)

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait